Analysts' Actions -- Ambarella, BlackBerry, PVH Corp., Zynga and More

RATINGS CHANGES

Ambarella (AMBA) was downgraded to sector weight at Pacific Crest.

BlackBerry (BBRY) was downgraded to market perform and assigned an $11 price target at Raymond James.

Hess (HES) was downgraded to neutral and assigned a $58 price target at Goldman Sachs.

Intuitive Surgical (ISRG) was downgraded to hold and assigned an $870 price target at Canaccord.

McKesson (MCK) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: MKC.

Marvell Technology (MRVL) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: MRVL.

Occidental Petroleum (OXY) was initiated with a neutral rating and $69 price target at MUFG.

PVH Corp. (PVH) was upgraded to outperform and assigned a $136 price target at Credit Suisse.

Simon Property Group (SPG) was upgraded to buy at Mizuho.

Symantec (SYMC) was upgraded to overweight and assigned a $38 price target at Barclays.

Tesoro (TSO) was upgraded to overweight at Morgan Stanley.

Valero Energy (VLO) was downgraded to equal-weight at Morgan Stanley.

Whiting Petroleum (WLL) was downgraded to sell and assigned a $7.25 price target at Goldman Sachs.

Cimarex (XEC) was downgraded to neutral and assigned a $133 price target at Goldman Sachs.

Zynga (ZNGA) was upgraded to overweight and assigned a $4 price target at Piper Jaffray.

This article was written by a staff member of TheStreet.

More from Stocks

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug